Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 60

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 60
---
.

| 1 | de Villiers MM, Aramwit P, Kwon GS. Nanotechnology in drug delivery. 
 New York: Springer; 2008                                             |

<div align='center'>37</div>

The superiority of liposomes as drug carriers has been widely recognized. Tens of liposomal and lipid-based formulations have been approved by regulatory authorities, and many liposomal drugs are in preclinical development or in clinical trials. Likewise, lipid nano-particles (LNP) have become the most promising non-viral delivery systems of nucleic acids (especially RNAi and in vitro transcribed (IVT) mRNA). Prof. Barenholz, the inventor of LipoVation nanoparticles-based portfolio, was the key inventor of Doxil™, the first FDA-approved nano-drug.

Recently, lipid nano-particles (LNP) have become one of the most promising non-viral delivery systems of nucleic acids, especially RNA and in vitro transcribed (IVT) mRNA. These have been widely implemented in the novel vaccines against Coronavirus by largest producers of the novel vaccines during the world pandemic in 2019-2020.

Companies that used LNPs ad delivery systems in COVID-19 Vaccines are:

| ● | One                                                                                         
 of the most prominent uses of LNP technology was in the Pfizer-BioNTech COVID-19 vaccine    
 Comirnaty. Pfizer collaborated with BioNTech, a German biotechnology company, to create one 
 of the first widely distributed mRNA vaccines. LNPs played a crucial role in ensuring the   
 stability and delivery of the mRNA encoding the spike protein of the virus.                 |

| ● | Moderna’s                                                                                       
 mRNA-based COVID-19 vaccine Spikevax, like Pfizer-BioNTech’s, relied on LNPs for the            
 delivery of its mRNA. Moderna was one of the pioneers in developing mRNA-based vaccines,        
 and the success of the LNP delivery system in this context was critical to the rapid deployment 
 of its vaccine.                                                                                 |

| ● | Arcturus                                                                                        
 developed another mRNA vaccine for COVID-19, also using LNPs for delivery. Although its vaccine 
 did not become as widely used as Pfizer-BioNTech or Moderna’s, it highlighted the growing       
 trend of using LNPs in mRNA vaccine development.                                                |

LNP technology, initially studied for delivering cancer therapeutics and other types of genetic materials (like siRNA), has also became essential in the broader field of nucleic acid therapies. The success of